友情提示：以下期刊信息可能会有更新，仅供参考，请在投稿前自行登录期刊官网仔细核实。
期刊名
BIOMEDICINE & PHARMACOTHERAPY
BIOMED PHARMACOTHER
ISSN / eISSN
0753-3322
目标和范围
Biomedicine & Pharmacotherapy is a multidisciplinary journal which publishes full-length, original research reports, reviews, and preliminary communications or letters to the editor which fall within the general scope of clinical and basic medicine and pharmacology.
The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases.
Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans.
Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers
The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases.
Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans.
Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers
研究方向
药学
医学：研究与实验
CiteScore
12.60
查看趋势图
CiteScore 学科排名
| 类别 | 分区 | 排名 |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics - Pharmacology | Q1 | #18/301 |
Web of Science 核心合集
| Science Citation Index Expanded (SCIE) | Social Sciences Citation Index (SSCI) |
|---|---|
| Indexed | - |
| 类别 (Journal Citation Reports 2023) | 分区 |
|---|---|
| MEDICINE, RESEARCH & EXPERIMENTAL - SCIE | Q1 |
| PHARMACOLOGY & PHARMACY - SCIE | Q1 |
H-index
78
出版国家或地区
FRANCE
出版商
Elsevier Masson
出版周期
Monthly
出版年份
1982
年文章数
1446
Open Access
NO
通讯方式
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, 23 RUE LINOIS, PARIS, FRANCE, 75724
认证评论
(I previously submitted it to Frontiers in Genetics, but the reviewer's rejection comments were very biased.)
Submitted on December 2, 2020
Revised on December 27, 2020, with the main suggestions being to provide code, experimental details and supplementary attachments, graphical abstract, and an open discussion (very gentle)
Uploaded revised files on January 21, 2021
Accepted on January 31, 2021, and the reviewer was very satisfied
Sent an email on February 19, 2021, asking about the proofreading timeline, and received a reply stating it would be revised within two working days
Originally thought it would be a Tier 3 journal, but surprisingly it was accepted in Tier 2. Hoping to make use of this article as soon as possible in 2021.
The only regret is that the journal warning list from the Chinese Academy of Sciences was not released when I submitted it.
I submitted on January 4th and a week later, they requested the WB original tapes to be supplemented (the result needs to be repeated three times, otherwise it will not be reviewed). After uploading the WB original tapes on January 14th, it was sent for external review on January 15th.
On January 28th, I received comments from two reviewers, both requiring minor revisions and the production of graphical abstracts, with a deadline of 20 days.
I uploaded the revised manuscript on February 14th at noon, and it was accepted on February 15th in the early morning.
Overall, the magazine's review speed is very fast. The magazine has high requirements for details.
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started